Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
|||
(10 intermediate revisions by 2 users not shown) | |||
Line 5: | Line 5: | ||
{{SK}} Apo A-1 Milano, ETC 216, MDCO 216 | {{SK}} Apo A-1 Milano, ETC 216, MDCO 216 | ||
==Official Title== | |||
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial | |||
==Objective== | ==Objective== | ||
*To study the effects of intravenous recombinant Apo A-1 Milano/[[phospholipid]] complexes (ETC-216) on arterial plaque burden in patients with [[acute coronary syndromes]] ([[ACS]]).<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref> | *To study the effects of intravenous recombinant Apo A-1 Milano/[[phospholipid]] complexes (ETC-216) on arterial plaque burden in patients with [[acute coronary syndromes]] ([[ACS]]).<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref> | ||
==Timeline== | ==Timeline== | ||
Line 21: | Line 21: | ||
| '''End Date'''||March 2003 | | '''End Date'''||March 2003 | ||
|- | |- | ||
| '''Status'''|| | | '''Status'''||Completed | ||
|- | |- | ||
|} | |} | ||
==Study Description== | ==Study Description== | ||
Line 40: | Line 39: | ||
| '''Allocation'''||Randomaized | | '''Allocation'''||Randomaized | ||
|- | |- | ||
| '''Endpoint'''|| | | '''Endpoint'''||Change in % atheroma volume on intravascular ultrasound (IVUS) | ||
|- | |- | ||
| '''Interventional Model'''||Parallel | | '''Interventional Model'''||Parallel | ||
Line 48: | Line 47: | ||
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Details''' | | Colspan="2" style="background:Gainsboro" align="center"|'''Study Details''' | ||
|- | |- | ||
| '''Primary Purpose'''|| | | '''Primary Purpose'''||Treatment | ||
|- | |- | ||
| '''Condition'''|| | | '''Condition'''||Acute coronary syndromes | ||
|- | |- | ||
| '''Intervention'''|| | | '''Intervention'''||Drug: ETC-216 | ||
|- | |- | ||
| '''Study Arms'''|| | | '''Study Arms'''||3 treatment groups in a respective ratio of approximatley 1:2:2 as follows: | ||
*Placebo - 0.9% normal saline (11 patients) | |||
*Low-dose ETC-216 - 15 mg/kg (21 patients) | |||
*High-dose ETC-216 - 45 mg/kg (15 patients) | |||
|- | |- | ||
| '''Population Size'''||123 | | '''Population Size'''|| | ||
*Patients enrolled: 123 | |||
*Patients randomly assigned: 57 | |||
*Patients completed protocol: 47 | |||
|- | |- | ||
|} | |} | ||
==Methods== | ==Methods== | ||
*A 5 week, randomized, double-blinded, multicenter, parallel-treatment [[randomized control trial]]<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref> | *A 5 week, randomized, double-blinded, multicenter, parallel-treatment [[randomized control trial]]<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref> | ||
*Patients enrolled: 123 patients | *Patients enrolled: 123 patients | ||
*Patients | *Patients completed the protocol: 47 patients | ||
IVUS was done at baseline. [[Intravenous infusion]] took place weekly for 5 consecutive weeks. Two weeks after infusion, [[IVUS]] was repeated for comparison.<ref name="pmid14600188">{{cite journal |author=Nissen SE, Tsunoda T, Tuzcu EM, ''et al.'' |title=Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial |journal=[[JAMA : the Journal of the American Medical Association]] |volume=290 |issue=17 |pages=2292–300 |year=2003 |month=November |pmid=14600188 |doi=10.1001/jama.290.17.2292 |url=}}</ref> | |||
==Eligibility Criteria== | ==Eligibility Criteria== | ||
===Inclusion Criteria=== | ===Inclusion Criteria=== | ||
Line 76: | Line 81: | ||
*Other [[anti-lipidemic drugs]] permitted during the study as long as no introduction or new medication or change in dosage occurs within 6 weeks of study start or end date. | *Other [[anti-lipidemic drugs]] permitted during the study as long as no introduction or new medication or change in dosage occurs within 6 weeks of study start or end date. | ||
===Outcomes=== | ===Outcomes=== | ||
====Primary Outcome==== | ====Primary Outcome==== | ||
Line 113: | Line 111: | ||
[[Category:HDL]] | [[Category:HDL]] | ||
[[Category:Clinical trials]] | [[Category:Clinical trials]] | ||
[[Category:HDLpedia]] |
Latest revision as of 14:40, 18 August 2014
High Density Lipoprotein Microchapters |
Diagnosis |
---|
Treatment |
Clinical Trials |
Case Studies |
Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes On the Web |
American Roentgen Ray Society Images of Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: : Rim Halaby, M.D. [2]
Synonyms and keywords: Apo A-1 Milano, ETC 216, MDCO 216
Official Title
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial
Objective
- To study the effects of intravenous recombinant Apo A-1 Milano/phospholipid complexes (ETC-216) on arterial plaque burden in patients with acute coronary syndromes (ACS).[1]
Timeline
Timeline | |
Start Date | November 2001 |
End Date | March 2003 |
Status | Completed |
Study Description
Study Description | |
Study Type | Interventional |
Study Phase | |
Study Design | |
Allocation | Randomaized |
Endpoint | Change in % atheroma volume on intravascular ultrasound (IVUS) |
Interventional Model | Parallel |
Masking | Double blind |
Study Details | |
Primary Purpose | Treatment |
Condition | Acute coronary syndromes |
Intervention | Drug: ETC-216 |
Study Arms | 3 treatment groups in a respective ratio of approximatley 1:2:2 as follows:
|
Population Size |
|
Methods
- A 5 week, randomized, double-blinded, multicenter, parallel-treatment randomized control trial[1]
- Patients enrolled: 123 patients
- Patients completed the protocol: 47 patients
IVUS was done at baseline. Intravenous infusion took place weekly for 5 consecutive weeks. Two weeks after infusion, IVUS was repeated for comparison.[1]
Eligibility Criteria
Inclusion Criteria
- Age: 30-75 years
- Angiography performed within 14 days following ACS event.
- At least 20% luminal diameter stenosis by visual estimated required
- Intravascular ultrasound (IVUS) done within 14 days of ACS event.
- No more than 50% luminal narrowing in a segment that is at least 30 mm in length.
- No previous percutaneous coronary intervention (PCI)
- Other anti-lipidemic drugs permitted during the study as long as no introduction or new medication or change in dosage occurs within 6 weeks of study start or end date.
Outcomes
Primary Outcome
Change in percent atheroma volume as measured by IVUS[1]
Secondary Outcomes
Assessment of adverse events, quantitative angiographic changes, change in average maximal thickness or in total volume of atheroma,or atheroma volume change in most and least severely diseases 10-mm-long segments.[1]
Publications
Results
- 10 patients were discontinued, while another 3 elected to discontinue
- 2 patients were withdrawn for adverse events
- 5 had IVUS that could not be analyzed
There was a significant difference in atheroma volume, mean change in total atheroma volume and thickness in the ETC-216 groups (combined) showing a 3.17% difference (p=0.02, p<0.001, p<0.001 respectively).[1] This statistical significance was not seen in patients on placebo. Most regression using ETC-216 was seen in subsegments of 10 mm long that are severely diseased, in comparison to those with only mild disease (p<0.001).[1]
However, luminal diameter on angiography was not different when comparing follow-up to baseline or when comparing ETC-216 vs. placebo.[1]
Adverse events included mainly minor gastrointestinal events, headaches,arthralgias, and edema that were found in all 3 groups. Two important adverse events that required withdrawal were:
- 1 patient with elevated liver function tests 3 times the upper normal limit with nausea vomiting, and cholelithiasis.[1]
- 1 patient with chills, rigors, rash, nausea, vomiting, and diaphoresis that occurred during infusion.[1]
Conclusion
Although Apo A-1 Milano infusions resulted in a decrease in plaque burden, further study is required to assess efficacy, safety and cost-effectiveness.[1]
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 Nissen SE, Tsunoda T, Tuzcu EM; et al. (2003). "Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial". JAMA : the Journal of the American Medical Association. 290 (17): 2292–300. doi:10.1001/jama.290.17.2292. PMID 14600188. Unknown parameter
|month=
ignored (help)